Glucotrack, Inc. (GCTK) Stock Price & Analysis
Glucotrack, Inc. (GCTK) fell 6.79% to USD 0.5 as of June 10, 2026 at 00:43 UTC, according to Nexqual real-time market data.
GCTK last closed at USD 0.54; the session ranged USD 0.5–0.56 on volume of 229,991 shares. Market capitalization is $3.14M, with a 52-week range of USD 0.43–15.9 (NCM). Source: Nexqual, June 10, 2026 at 00:43 UTC.
Key Statistics (as of June 10, 2026 at 00:43 UTC)
| Price | USD 0.5 |
|---|---|
| Change | ▼ 6.79% (down) |
| Previous Close | USD 0.54 |
| Open | USD 0.54 |
| Day Range | USD 0.5 – 0.56 |
| 52-Week Range | USD 0.43 – 15.9 |
| Volume | 229,991 shares |
| Market Cap | $3.14M |
| Exchange | NCM |
Technical Analysis (GCTK)
Nexqual's technical model rates GCTK "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.77 (neutral) |
| vs SMA50 | Below (USD 0.7) |
| MACD | -0.05 (negative) |
Analyst Ratings (GCTK)
Wall Street analysts rate GCTK "None", per Nexqual as of June 10, 2026 at 00:43 UTC.
| Consensus Rating | None |
|---|
Earnings (GCTK)
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Financials & Fundamentals (GCTK)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -527.21% |
| Current Ratio | 0.85 |
| Total Cash | $3.93M |
| Total Debt | $3.59M |
| Free Cash Flow | $-10.13M |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Financial Health Score (GCTK)
Nexqual rates Glucotrack, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $4M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$16M |
| Efficiency | Critical — ROE -527%, ROA -150.3% |
Ownership (GCTK)
| Insider Ownership | +0.94% |
|---|---|
| Institutional Ownership | +4.34% |
| Shares Outstanding | 6.26M |
| Float | 6.16M |
| Short % of Float | +0.70% |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Leadership (GCTK)
Glucotrack, Inc. is led by Paul V. Goode (age 56), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:43 UTC.
| CEO, President & Director | Paul V. Goode (age 56) |
|---|---|
| Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board | Avner Gal MBA, MSc.EE (age 71) |
| Chief Scientific Officer | Mark Tapsak (age 56) |
| Vice President of Marketing | Drinda Benjamin (age 49) |
Major Backers & Investors (GCTK)
Notable institutional backers of Glucotrack, Inc. include Fidelity, Ikarian Capital, LLC, HRT Financial LP, according to Nexqual as of June 10, 2026 at 00:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.74% |
| Ikarian Capital, LLC | 0.73% |
| HRT Financial LP | 0.65% |
| Boothbay Fund Management, LLC | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.75% |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
From Glucotrack, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development.   Further to the above progress on the Glucotrack CBGM, we have also successfully demonstrated continuous glucose sensing in the epidural space.
- Our approach is based on design elements, implant techniques, and implant tools commonly used for active implantable devices in the cardiovascular space.
- Since then, we have developed a dual supply source for both implantable system components (the electronics assembly and the sensor lead), both of which are ISO 13485 certified with dedicated experience in manufacturing active implantable medical devices.
- This will enable us to craft a reimbursement strategy that is best suited to our Glucotrack CBGM and reflects the different healthcare providers that may be involved in utilizing the product.   Our reimbursement strategy also incorporates coverage for the product, the implantation procedure, and the removal and reinsertion procedures.
Partnerships
- Both organizations have since manufactured products used in various Glucotrack pre-clinical bench and animal studies, as well products used in both our human clinical trials.   Also in 2024, we worked with The Technology Partnership, or "TTP" (Cambridge, UK) to demonstrate a sensor longevity of 3 years.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACON | Aclarion, Inc. | USD 3.26 | ▼ 8.68% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| SOBR | SOBR Safe, Inc. | USD 0.75 | ▼ 26.86% |
| SKYA | SkyAI, Inc. | USD 1.16 | ▼ 4.13% |
| NEXR | Nexera Technologies Ltd | USD 0.8 | ▼ 33.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:43 UTC. This page is informational and not investment advice.